Literature DB >> 9528800

Shc and Enigma are both required for mitogenic signaling by Ret/ptc2.

K Durick1, G N Gill, S S Taylor.   

Abstract

Ret/ptc2 is a constitutively active, oncogenic form of the c-Ret receptor tyrosine kinase. Like the other papillary thyroid carcinoma forms of Ret, Ret/ptc2 is activated through fusion of the Ret tyrosine kinase domain to the dimerization domain of another protein. Investigation of requirements for Ret/ptc2 mitogenic activity, using coexpression with dominant negative forms of Ras and Raf, indicated that these proteins are required for mitogenic signaling by Ret/ptc2. Because activation of Ras requires recruitment of Grb2 and SOS to the plasma membrane, the subcellular distribution of Ret/ptc2 was investigated, and it was found to localize to the cell periphery. This localization was mediated by association with Enigma via the Ret/ptc2 sequence containing tyrosine 586. Because Shc interacts with MEN2 forms of Ret, and because phosphorylation of Shc results in Grb2 recruitment and subsequent signaling through Ras and Raf, the potential interaction between Ret/ptc2 and Shc was investigated. The PTB domain of Shc also interacted with Ret/ptc2 at tyrosine 586, and this association resulted in tyrosine phosphorylation of Shc. Coexpression of chimeric proteins demonstrated that mitogenic signaling from Ret/ptc2 required both recruitment of Shc and subcellular localization by Enigma. Because Shc and Enigma interact with the same site on a Ret/ptc2 monomer, dimerization of Ret/ptc2 allows assembly of molecular complexes that are properly localized via Enigma and transmit mitogenic signals via Shc.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9528800      PMCID: PMC121481          DOI: 10.1128/MCB.18.4.2298

Source DB:  PubMed          Journal:  Mol Cell Biol        ISSN: 0270-7306            Impact factor:   4.272


  57 in total

1.  Neurturin responsiveness requires a GPI-linked receptor and the Ret receptor tyrosine kinase.

Authors:  A Buj-Bello; J Adu; L G Piñón; A Horton; J Thompson; A Rosenthal; M Chinchetru; V L Buchman; A M Davies
Journal:  Nature       Date:  1997-06-12       Impact factor: 49.962

2.  Domain interaction between NMDA receptor subunits and the postsynaptic density protein PSD-95.

Authors:  H C Kornau; L T Schenker; M B Kennedy; P H Seeburg
Journal:  Science       Date:  1995-09-22       Impact factor: 47.728

3.  Raf-1 N-terminal sequences necessary for Ras-Raf interaction and signal transduction.

Authors:  K Pumiglia; Y H Chow; J Fabian; D Morrison; S Decker; R Jove
Journal:  Mol Cell Biol       Date:  1995-01       Impact factor: 4.272

Review 4.  Receptor protein-tyrosine kinases and their signal transduction pathways.

Authors:  P van der Geer; T Hunter; R A Lindberg
Journal:  Annu Rev Cell Biol       Date:  1994

5.  Specificity of the PTB domain of Shc for beta turn-forming pentapeptide motifs amino-terminal to phosphotyrosine.

Authors:  T Trüb; W E Choi; G Wolf; E Ottinger; Y Chen; M Weiss; S E Shoelson
Journal:  J Biol Chem       Date:  1995-08-04       Impact factor: 5.157

6.  Tyrosines outside the kinase core and dimerization are required for the mitogenic activity of RET/ptc2.

Authors:  K Durick; V J Yao; M G Borrello; I Bongarzone; M A Pierotti; S S Taylor
Journal:  J Biol Chem       Date:  1995-10-20       Impact factor: 5.157

7.  LIM domain recognition of a tyrosine-containing tight turn.

Authors:  R Y Wu; G N Gill
Journal:  J Biol Chem       Date:  1994-10-07       Impact factor: 5.157

8.  Targeted expression of the ret/PTC1 oncogene induces papillary thyroid carcinomas.

Authors:  S M Jhiang; J E Sagartz; Q Tong; J Parker-Thornburg; C C Capen; J Y Cho; S Xing; C Ledent
Journal:  Endocrinology       Date:  1996-01       Impact factor: 4.736

9.  A 7 bp deletion of the RET proto-oncogene in familial Hirschsprung's disease.

Authors:  T Attie; A Pelet; P Sarda; C Eng; P Edery; L M Mulligan; B A Ponder; A Munnich; S Lyonnet
Journal:  Hum Mol Genet       Date:  1994-08       Impact factor: 6.150

10.  Phosphotyrosine-dependent interaction of SHC and insulin receptor substrate 1 with the NPEY motif of the insulin receptor via a novel non-SH2 domain.

Authors:  T A Gustafson; W He; A Craparo; C D Schaub; T J O'Neill
Journal:  Mol Cell Biol       Date:  1995-05       Impact factor: 4.272

View more
  16 in total

1.  The PDZ domain of the LIM protein enigma binds to beta-tropomyosin.

Authors:  P M Guy; D A Kenny; G N Gill
Journal:  Mol Biol Cell       Date:  1999-06       Impact factor: 4.138

2.  LMP1 regulates periodontal ligament progenitor cell proliferation and differentiation.

Authors:  Zhao Lin; Valeria Pontelli Navarro; Kathryn M Kempeinen; Lea M Franco; Qiming Jin; James V Sugai; William V Giannobile
Journal:  Bone       Date:  2010-03-27       Impact factor: 4.398

3.  Enigma interacts with adaptor protein with PH and SH2 domains to control insulin-induced actin cytoskeleton remodeling and glucose transporter 4 translocation.

Authors:  Romain Barrès; Thierry Grémeaux; Philippe Gual; Teresa Gonzalez; Jean Gugenheim; Albert Tran; Yannick Le Marchand-Brustel; Jean-François Tanti
Journal:  Mol Endocrinol       Date:  2006-06-27

4.  Mystique is a new insulin-like growth factor-I-regulated PDZ-LIM domain protein that promotes cell attachment and migration and suppresses Anchorage-independent growth.

Authors:  Gary Loughran; Nollaig C Healy; Patrick A Kiely; Merei Huigsloot; Nancy L Kedersha; Rosemary O'Connor
Journal:  Mol Biol Cell       Date:  2005-01-19       Impact factor: 4.138

5.  Docking protein FRS2 links the protein tyrosine kinase RET and its oncogenic forms with the mitogen-activated protein kinase signaling cascade.

Authors:  R M Melillo; M Santoro; S H Ong; M Billaud; A Fusco; Y R Hadari; J Schlessinger; I Lax
Journal:  Mol Cell Biol       Date:  2001-07       Impact factor: 4.272

6.  Internalization of glial cell-derived neurotrophic factor receptor GFR alpha 1 in the absence of the ret tyrosine kinase coreceptor.

Authors:  P Vieira; J Thomas-Crusells; A Vieira
Journal:  Cell Mol Neurobiol       Date:  2003-02       Impact factor: 5.046

Review 7.  Multiple endocrine neoplasia type 2 and RET: from neoplasia to neurogenesis.

Authors:  J R Hansford; L M Mulligan
Journal:  J Med Genet       Date:  2000-11       Impact factor: 6.318

Review 8.  Nucleocytoplasmic functions of the PDZ-LIM protein family: new insights into organ development.

Authors:  Jennifer Krcmery; Troy Camarata; Andre Kulisz; Hans-Georg Simon
Journal:  Bioessays       Date:  2010-02       Impact factor: 4.345

9.  RET/PTC-induced cell growth is mediated in part by epidermal growth factor receptor (EGFR) activation: evidence for molecular and functional interactions between RET and EGFR.

Authors:  Michelle Croyle; Nagako Akeno; Jeffrey A Knauf; Doriano Fabbro; Xu Chen; Jacqueline E Baumgartner; Heidi A Lane; James A Fagin
Journal:  Cancer Res       Date:  2008-06-01       Impact factor: 12.701

Review 10.  ALP/Enigma PDZ-LIM domain proteins in the heart.

Authors:  Ming Zheng; Hongqiang Cheng; Indroneal Banerjee; Ju Chen
Journal:  J Mol Cell Biol       Date:  2009-12-30       Impact factor: 6.216

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.